BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme
BioMarin, multiple quarters into its portfolio refinement, is inking a small acquisition for a rare disease therapy about two years before a potential regulatory approval. The California drugmaker plans to buy Boston-based Inozyme Pharma and ...
BioMarin, multiple quarters into its portfolio refinement, is inking a small acquisition for a rare disease therapy about two years before a potential regulatory approval.
The California drugmaker plans to buy Boston-based Inozyme Pharma and ...
